Program
niraparib
Also written as “Niraparib”, “MK-4827” and “ZL-2306(nirapairb)”.
Its studies are mostly in Ovarian Neoplasms · Neoplasms · Prostatic Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 236 open or running | phase 4since Mar 19, 2025 | Sep 5, 2008 | Nov 26, 2026phase 3 · NCT03981796 |
| Johnson & Johnson | 53 open or running | phase 3since Nov 19, 2018 | Aug 1, 2016 | none ahead |
| Zai Lab | 50 open or running | phase 3since Apr 23, 2018 | Apr 20, 2018 | none ahead |
| Takeda | 30 open or running | phase 2since Nov 29, 2018 | Apr 5, 2018 | none ahead |
| Merck | 20 open or running | phase 1since Oct 21, 2010 | Oct 21, 2010 | none ahead |
| Tempus AI | 10 open or running | phase 2since Dec 13, 2021 | Dec 13, 2021 | none ahead |
Also a collaborator on its studies: myriad-genetics-inc, Sarah Cannon Research Institute, sarah-cannon and myriad-genetic-laboratories-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Sep 5, 2008.
- Sep 19, 20182 phase 3 studiesZai Lab · NCT03709316, NCT03705156
- Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
- Nov 29, 20182 phase 2 studies in Ovarian NeoplasmsTakeda · NCT03759600, NCT03759587
- May 31, 2019Phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796 · 785 enrolled · United States, Belarus, Belgium and more
- May 13, 2020Phase 2 study in Ovarian NeoplasmsZai Lab · NCT04392102 · 15 enrolled · China
- Jul 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT04475939 · 666 enrolled · United States, Argentina, Australia and more
- Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
- Sep 4, 2020Phase 1 study in NeoplasmsGlaxoSmithKline · NCT04544995 · 47 enrolled · United Kingdom
- Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
- Nov 20, 2020Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247 · 37 planned · United States, Austria, Canada and more
- Jun 1, 2021Phase 3 study in Breast NeoplasmsGlaxoSmithKline · NCT04915755 · 40 enrolled · United States, Argentina, Australia and more
- Dec 13, 2021Tempus AI's first study: phase 2 study in Breast NeoplasmsNew to Tempus AITempus AI · NCT05169437 · 22 enrolled · United States
- Mar 19, 2025Phase 4 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06887933 · 67 planned
- Apr 30, 2025Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06964165 · 36 enrolled · United States, Canada, Spain
Ahead
- Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
- Dec 28, 2026Primary completion: phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247
TargetBeta
“Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06964165Ovarian Neoplasms · United States, Canada, Spain | 2 | Terminated | GlaxoSmithKline | Jun 28, 2024 | 36 |
| NCT06887933Ovarian Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Mar 20, 2026 | 67 |
| NCT05169437Breast Neoplasms · United States | 2 | Terminated | Tempus AI | Aug 6, 2024 | 22 |
| NCT04915755Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 28, 2024 | 40 |
| NCT04641247Ovarian Neoplasms · United States, Austria, Canada and more | 2 | Recruiting | GlaxoSmithKline | Dec 28, 2026 | 37 |
| NCT04577833Prostatic Neoplasms · United States, Belgium, France and more | 1 | Active, not recruiting | Johnson & Johnson | Oct 15, 2021 | 136 |
| NCT04544995Neoplasms · United Kingdom | 1 | Terminated | GlaxoSmithKline | Apr 23, 2025 | 47 |
| NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 7, 2025 | 696 |
| NCT04475939Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Feb 26, 2025 | 666 |
| NCT04392102Ovarian Neoplasms · China | 2 | Completed | Zai Lab | Apr 8, 2021 | 15 |
| NCT03981796Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Nov 26, 2026 | 785 |
| NCT03759600Ovarian Neoplasms · Japan | 2 | Completed | Takeda | Dec 28, 2022 | 20 |
| NCT03759587Ovarian Neoplasms · Japan | 2 | Completed | Takeda | Mar 17, 2019 | 19 |
| NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 8, 2021 | 765 |
| NCT03709316Ovarian Neoplasms · China | 3 | UNKNOWN | Zai Lab | Jan 29, 2022 | 384 |
| NCT03705156Platinum-sensitive Relapsed Ovarian Cancer · China | 3 | UNKNOWN | Zai Lab | Feb 1, 2020 | 265 |
| NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Oct 31, 2024 | 1,400 |
| NCT03516084Small Cell Lung Carcinoma · China | 3 | Terminated | Zai Lab | Feb 21, 2020 | 185 |
| NCT03551171Ovarian Neoplasms · China | 1 | Completed | Zai Lab | May 3, 2018 | 42 |
| NCT03497429Advanced Solid Tumors · Japan | 1 | Completed | Takeda | Feb 10, 2020 | 9 |
| NCT03329001Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Dec 30, 2021 | 236 |
| NCT03329937Breast Neoplasms | 1 | Completed | GlaxoSmithKline | Jan 2, 2020 | 21 |
| NCT03326193Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Dec 24, 2020 | 105 |
| NCT03359850Ovarian Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Sep 16, 2019 | 17 |
| NCT03308942Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 4, 2020 | 53 |
| NCT02924766Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Jul 18, 2019 | 34 |
| NCT02854436Prostatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Johnson & Johnson | Jan 26, 2021 | 289 |
| NCT02657889Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 14, 2018 | 122 |
| NCT02655016Ovarian Neoplasms · United States, Belgium, Denmark and more | 3 | Active, not recruiting | GlaxoSmithKline | May 17, 2019 | 733 |
| NCT02476552Neoplasms · Netherlands | 1 | Completed | GlaxoSmithKline | Dec 2015 | 12 |
| NCT02354586Ovarian Neoplasms · United States, Canada | 2 | Completed | GlaxoSmithKline | Feb 28, 2018 | 463 |
| NCT01905592Breast Neoplasms · United States, Belgium, Canada and more | 3 | Terminated | GlaxoSmithKline | May 23, 2018 | 216 |
| NCT01847274Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 22, 2016 | 596 |
| NCT01294735Glioblastoma | 1 | Completed | Merck | Apr 2012 | 19 |
| NCT01244009Lymphoma | 2 | Withdrawn | GlaxoSmithKline | Aug 2013 | 0 |
| NCT01227941Ovarian Neoplasms | 1 | Terminated | GlaxoSmithKline | Sep 2011 | 6 |
| NCT01226901Neoplasms | 1 | Terminated | Merck | Feb 2011 | 3 |
| NCT01110603Neoplasms | 1 | Terminated | GlaxoSmithKline | Jul 2011 | 12 |
| NCT00749502Leukemia, Lymphocytic, Chronic, B-Cell | 1 | Completed | GlaxoSmithKline | Sep 2011 | 113 |
How it is read
Names in the registry
- “Niraparib”, 25 entries
- “MK-4827”, 5 entries
- “ZL-2306(nirapairb)”, 2 entries
- “niraparib”, 2 entries
- “MK-4827 + pegylated liposomal doxorubicin”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 18 studies
- Neoplasms, 9 studies
- Prostatic Neoplasms, 4 studies
- Breast Neoplasms, 3 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.